personal care revenues recorded at THB 678 million, an increase of 0.5% YoY). The growth driver were the continued success of Babi Mild from the momentum of Babi Mild Sweet Almond range launched in Q2’19 and
distributors. Personal Care Segment Total revenues from sales of Personal Care segment decreased by THB 30.3 million (or -4.8% YoY) from higher base last year from strong promotions for Babi Mild and Twelve Plus
March, as customers gear towards health and hygiene products. As a result, Babi Mild continues to show strong growth momentum from liquid soap and cleaning products together with the recent relaunches of
growth. Turning crisis into opportunity, OSP promptly responded to health and hygiene trend with hand sanitizer products via OEM operation and own product launches under various brands, namely Babi Mild
. Shareholders’ Equity As of 31 March 2019, the Company held shareholders’ equity of THB 4,998.70 million. The mild increase in shareholders’ equity of 0.32% was mainly derived from rising retained earnings
1,664.5 1,899.4 1,148.8 (234.9) (12.4) 515.8 44.9 Profit for the period 121.3 146.9 59.7 (25.6) (14.4) 61.6 103.2 Overall of the Thai economy in the middle of the Q1–2021 gradually improved after the mild
1,664.5 1,899.4 1,148.8 (234.9) (12.4) 515.8 44.9 Profit for the period 121.3 146.9 59.7 (25.6) (14.4) 61.6 103.2 Overall of the Thai economy in the middle of the Q1–2021 gradually improved after the mild
property, plant and equipment. Cash spent and repayments of loans from financial institutions mainly contributed to the mild drop in total assets. Total Liabilities As of 30 June 2019, the Company held total
mild drop in total assets. Total Liabilities As of 30 September 2019, the Company held total liabilities of THB 144.92 million, falling at a rate of 45.41% from the end of last year. Total liabilities
-in sales from the pandemic control measures in endemic areas and consumers’ concerns over the situation. However, this was a relatively mild decline due to the company launching promotions to drive